GLTO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GLTO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Galecto has the Momentum Rank of 4.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Galecto's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Galecto's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Galecto's Momentum Rank falls into.
Thank you for viewing the detailed overview of Galecto's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Bertil Lindmark | officer: Chief Medical Officer | C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200 |
Hans T. Schambye | director, officer: Chief Executive Officer | C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200 |
Stephanie Oestreich | officer: Chief Business Officer | 75 STATE STREET, SUITE 100, BOSTON MA 02109 |
Jonathan Freve | officer: Chief Financial Officer | C/O SPRING BANK PHARMACEUTICALS, INC., 113 CEDAR STREET, STE S-7, MILFORD MA 01757 |
Garrett Winslow | officer: General Counsel | 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748 |
Anne Prener | director | C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139 |
Dallas Jayson Donald Alexander | director | AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Chau Quang Khuong | director, 10 percent owner | C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Stephan Christgau | director | C/O CASTLE & MORGAN HOLDINGS, INC., 425 MARKET STREET, SUITE 2230, SAN FRANCISCO CA 94105 |
Soren Moller | director | C/O NOVO HOLDINGS A/S, TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Anders Pedersen | officer: Chief Operating Officer | C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200 |
Orbimed Advisors Israel Ii Ltd | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Israel Gp Ii, L.p. | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Marketwired • 08-31-2023
By sperokesalga sperokesalga • 06-20-2023
By GuruFocusNews GuruFocusNews • 07-10-2022
By GuruFocusNews GuruFocusNews • 06-30-2022
By PurpleRose PurpleRose • 07-29-2022
By PurpleRose PurpleRose • 07-15-2022
By GuruFocusNews GuruFocusNews • 06-20-2022
By Ds*** Ds*** • 08-29-2022
By Value_Insider Value_Insider • 11-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.